

January 21, 2025

**BSE Limited** Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 <u>Scrip code: 532531</u> **The National Stock Exchange of India Limited** Exchange Plaza, Bandra-Kurla Complex Bandra (E) Mumbai - 400 051 <u>Scrip code: STAR</u>

Dear Madam/ Sir,

## Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations)

We would like to inform you that the Company has received an Order on January 20, 2024 from the Transfer Pricing Officer being issued under Section 92 CA (3) of the Income Tax Act, 1961 for the Assessment Year 2022-23.

Disclosure under Regulation 30 of SEBI Listing Regulations is enclosed for your information and records.

Thanks & Regards, For **Strides Pharma Science Limited**,

Manjula Ramamurthy Company Secretary ICSI Membership No. A30515

Encl. As above



## Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015

#	Particulars	Remarks
a)	Name of the opposing party	The Office of Joint Commissioner of Income tax, Transfer Pricing ADDL/JCIT TP(4)(1), Mumbai
b)	Brief details of Dispute/ Litigation	Company has received an Order from the Transfer Pricing Officer being issued under Section 92 CA (3) of the Income Tax Act, 1961 for Assessment Year (AY) 2022-23, wherein an adjustment on a specific issue has been proposed.
c)	Court/ Tribunal/ Agency where the Litigation is filed	The matter will be challenged before appropriate appellate forum once the draft order is received by March 31, 2025
d)	Expected financial implications, if any, due to compensation, penalty etc; & Quantum of claims, if any	The expected overall financial implication cannot be determined at this stage. It will be determined only upon passing of the draft assessment order for AY 2022- 23.

\*\*\*\*\*